-DOCSTART-	O

Title	O
:	O
Magnesium	B-I
treatment	I-I
on	O
methylation	O
changes	O
of	O
transmembrane	O
serine	O
protease	O
2	O
(	O
TMPRSS2	O
)	O
.	O

METHODS	O
:	O
This	O
study	O
is	O
nested	O
within	O
the	O
Personalized	O
Prevention	O
of	O
Colorectal	O
Cancer	O
Trial	O
,	O
a	O
double	O
-	O
blind	O
2	O
	O
2	O
factorial	O
randomized	O
controlled	O
trial	O
,	O
which	O
enrolled	O
250	B-P
participants	I-P
from	I-P
Vanderbilt	I-P
University	I-P
Medical	I-P
Center	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Feasibility	O
and	O
outcome	O
of	O
an	B-I
online	I-I
streamed	I-I
yoga	I-I
intervention	I-I
on	O
stress	O
and	O
wellbeing	O
of	O
people	B-P
working	I-P
from	I-P
home	I-P
during	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	O
six	O
-	O
week	O
pilot	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
yoga	O
intervention	O
was	O
designed	O
with	O
yoga	B-I
(	O
n	O
=	O
26	O
)	O
and	O
a	B-C
wait	I-C
-	I-C
list	I-C
control	I-C
group	O
(	O
n	O
=	O
26	O
)	O
.	O

A	O
mixed	O
two	O
-	O
way	O
ANOVA	O
was	O
used	O
to	O
assess	O
changes	O
in	O
standardised	O
outcome	O
measures	O
at	O
baseline	O
and	O
post	O
-	O
intervention	O
.	O

Likert	B-O
and	O
open	B-O
-	I-O
ended	I-O
questions	I-O
assessed	O
enjoyment	B-O
,	O
acceptability	B-O
and	O
perceived	B-O
benefits	I-O
of	I-O
the	I-O
program	I-O
,	O
which	O
were	O
analysed	O
thematically	O
.	O

-DOCSTART-	O

Title	O
:	O
Discontinuation	B-I
versus	O
continuation	B-I
of	I-I
renin	I-I
-	I-I
angiotensin	I-I
-	I-I
system	I-I
inhibitors	I-I
in	O
COVID	O
-	O
19	O
(	O
ACEI	O
-	O
COVID	O
)	O
:	O
a	O
prospective	O
,	O
parallel	O
group	O
,	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
.	O

METHODS	O
:	O
ACEI	O
-	O
COVID	O
was	O
a	O
parallel	O
group	O
,	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
done	O
at	O
35	O
centres	O
in	O
Austria	O
and	O
Germany	O
.	O

Patients	B-P
aged	I-P
18	I-P
years	I-P
and	I-P
older	I-P
were	O
enrolled	O
if	O
they	O
presented	O
with	O
recent	O
symptomatic	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
and	O
were	O
chronically	O
treated	O
with	O
ACEIs	O
or	O
ARBs	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
discontinuation	B-I
or	O
continuation	B-I
of	I-I
RAS	I-I
inhibition	I-I
for	O
30	O
days	O
.	O

Primary	O
outcome	O
was	O
the	B-O
maximum	I-O
sequential	I-O
organ	I-O
failure	I-O
assessment	I-O
(	I-O
SOFA	I-O
)	I-O
score	I-O
within	O
30	O
days	O
,	O
where	O
death	O
was	O
scored	O
with	O
the	O
maximum	O
achievable	O
SOFA	O
score	O
.	O

Secondary	O
endpoints	O
were	O
area	B-O
under	I-O
the	I-O
death	I-O
-	I-O
adjusted	I-O
SOFA	I-O
score	I-O
(	I-O
AUCSOFA	I-O
)	I-O
,	O
mean	B-O
SOFA	I-O
score	I-O
,	O
admission	B-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
,	O
mechanical	B-O
ventilation	I-O
,	O
and	O
death	B-O
.	O

Analyses	O
were	O
done	O
on	O
a	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04353596	O
.	O

-DOCSTART-	O

Title	O
:	O
Traditional	B-I
Chinese	I-I
medicine	I-I
shenhuang	I-I
granule	I-I
in	O
patients	B-P
with	I-P
severe	I-P
/	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
an	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

At	O
4	O
medical	O
centers	O
,	O
a	B-P
total	I-P
of	I-P
111	I-P
severe	I-P
/	I-P
critical	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
Shenhuang	B-I
Granule	I-I
(	O
SHG	B-I
group	O
)	O
twice	O
a	O
day	O
for	O
14	O
days	O
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
to	O
receive	O
standard	B-C
care	I-C
alone	I-C
(	O
Control	O
group	O
)	O
.	O

The	O
maximal	O
follow	O
up	O
time	O
was	O
75	O
days	O
.	O

The	O
clinical	O
endpoint	O
was	O
clinical	O
improvement	O
and	O
mortality	O
.	O

-DOCSTART-	O

Title	O
:	O
Tofacitinib	B-I
in	O
Patients	B-P
Hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
Pneumonia	I-P
.	O

METHODS	O
:	O
We	O
randomly	O
assigned	O
,	O
in	O
a	O
1	O
:	O
1	O
ratio	O
,	O
hospitalized	B-P
adults	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
to	O
receive	O
either	O
tofacitinib	B-I
at	O
a	O
dose	O
of	O
10	O
mg	O
or	O
placebo	B-C
twice	O
daily	O
for	O
up	O
to	O
14	O
days	O
or	O
until	O
hospital	O
discharge	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
occurrence	I-O
of	I-O
death	I-O
or	O
respiratory	B-O
failure	I-O
through	O
day	O
28	O
as	O
assessed	O
with	O
the	B-O
use	I-O
of	I-O
an	I-O
eight	I-O
-	I-O
level	I-O
ordinal	I-O
scale	I-O
(	O
with	O
scores	O
ranging	O
from	O
1	O
to	O
8	O
and	O
higher	O
scores	O
indicating	O
a	O
worse	O
condition	O
)	O
.	O

All	B-O
-	I-O
cause	I-O
mortality	I-O
and	O
safety	B-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
efficacy	O
and	O
safety	O
of	O
hydroxychloroquine	B-I
as	O
outpatient	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
Alberta	O
during	O
the	O
first	O
wave	O
of	O
the	O
COVID	O
-	O
19	O
pandemic	O
without	O
direct	O
contact	O
with	O
participants	O
.	O

Community	B-P
-	I-P
dwelling	I-P
individuals	I-P
with	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
(	I-P
by	I-P
reverse	I-P
transcription	I-P
polymerase	I-P
chain	I-P
reaction	I-P
[	I-P
RT	I-P
-	I-P
PCR	I-P
]	I-P
viral	I-P
ribonucleic	I-P
acid	I-P
test	I-P
)	I-P
within	I-P
the	I-P
previous	I-P
4	I-P
days	I-P
,	I-P
and	I-P
symptom	I-P
onset	I-P
within	I-P
the	I-P
previous	I-P
12	I-P
days	I-P
,	O
were	O
randomly	O
assigned	O
to	O
oral	B-I
hydroxychloroquine	I-I
or	O
matching	B-C
placebo	I-C
for	O
5	O
days	O
.	O

Enrolment	O
began	O
Apr	O
.	O

15	O
,	O
2020	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
composite	I-O
of	I-O
hospitalization	I-O
,	O
invasive	B-O
mechanical	I-O
ventilation	I-O
or	O
death	B-O
within	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
symptom	B-O
duration	I-O
and	O
disposition	B-O
at	O
30	O
days	O
.	O

Safety	B-O
outcomes	I-O
,	O
such	O
as	O
serious	B-O
adverse	I-O
events	I-O
and	O
mortality	B-O
,	O
were	O
also	O
ascertained	O
.	O

Outcomes	O
were	O
determined	O
by	O
telephone	O
follow	O
-	O
up	O
and	O
administrative	O
data	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
clinical	O
trial	O
"	O
olfactory	O
dysfunction	O
after	O
COVID	O
-	O
19	O
:	O
olfactory	B-C
rehabilitation	I-C
therapy	I-C
vs	O
.	O
intervention	O
treatment	O
with	O
Palmitoylethanolamide	B-I
and	O
Luteolin	B-I
"	O
:	O
preliminary	O
results	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
-	O
controlled	O
pilot	O
study	O
in	O
outpatients	B-P
with	I-P
history	I-P
of	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
with	I-P
post	I-P
-	I-P
infection	I-P
olfactory	I-P
impairment	I-P
that	I-P
persisted	I-P
?	I-P
90	I-P
days	I-P
after	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
negative	I-P
testing	I-P
.	O

Patients	O
were	O
randomized	O
to	O
two	B-C
times	I-C
a	I-C
day	I-C
olfactory	I-C
rehabilitation	I-C
alone	I-C
or	O
weekly	B-I
olfactory	I-I
rehabilitation	I-I
plus	O
daily	B-I
oral	I-I
supplement	I-I
with	I-I
PEA	I-I
and	O
Luteolin	B-I
.	O

Subjects	O
with	O
preexisting	O
olfactory	O
disorders	O
were	O
excluded	O
.	O

Sniffin	B-O
'	I-O
Sticks	I-O
assessments	I-O
were	O
performed	O
at	O
baseline	O
and	O
30	O
days	O
after	O
treatment	O
.	O

Data	O
on	O
gender	O
,	O
age	O
,	O
and	O
time	O
since	O
infection	O
were	O
collected	O
.	O

Kruskal	O
-	O
Wallis	O
(	O
KW	O
)	O
test	O
was	O
used	O
to	O
compare	O
variances	O
of	O
Sniff	O
scores	O
between	O
groups	O
over	O
time	O
,	O
and	O
Spearman	O
'	O
s	O
correlation	O
coefficients	O
were	O
calculated	O
to	O
assess	O
for	O
correlations	O
between	O
Sniff	O
Score	O
and	O
gender	O
or	O
duration	O
of	O
infection	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
,	O
Biochemical	O
and	O
Molecular	O
Evaluations	O
of	O
Ivermectin	B-I
Mucoadhesive	I-I
Nanosuspension	I-I
Nasal	I-I
Spray	I-I
in	O
Reducing	O
Upper	O
Respiratory	O
Symptoms	O
of	O
Mild	O
COVID	O
-	O
19	O
.	O

METHODS	O
:	O
This	O
clinical	O
trial	O
included	O
114	B-P
patients	I-P
diagnosed	I-P
as	I-P
mild	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
divided	O
randomly	O
into	O
two	O
age	O
and	O
sex	O
-	O
matched	O
groups	O
;	O
group	O
A	O
comprising	O
57	O
patients	O
received	O
ivermectin	B-I
nanosuspension	I-I
nasal	I-I
spray	I-I
twice	O
daily	O
plus	O
the	B-I
Egyptian	I-I
protocol	I-I
of	I-I
treatment	I-I
for	I-I
mild	I-I
COVID	I-I
-	I-I
19	I-I
and	O
group	O
B	O
comprising	O
57	O
patients	O
received	O
the	B-C
Egyptian	I-C
protocol	I-C
for	I-C
mild	I-C
COVID	I-C
-	I-C
19	I-C
only	I-C
.	O

Evaluation	O
of	O
the	O
patients	O
was	O
performed	O
depending	O
on	O
improvement	B-O
of	I-O
presenting	I-O
manifestations	I-O
,	O
negativity	B-O
of	I-O
two	I-O
consecutive	I-O
pharyngeal	I-O
swabs	I-O
for	I-O
the	I-O
COVID	I-O
-	I-O
19	I-O
nucleic	I-O
acid	I-O
via	O
rRT	B-O
-	I-O
PCR	I-O
and	O
assessments	O
of	O
hematological	B-O
and	O
biochemical	B-O
parameters	I-O
in	I-O
the	I-O
form	I-O
of	I-O
complete	I-O
blood	I-O
counts	I-O
,	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
,	O
serum	B-O
ferritin	I-O
and	O
d	B-O
-	I-O
dimer	I-O
which	O
were	O
performed	O
at	O
presentation	O
and	O
7	O
days	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
narrative	B-I
exposure	I-I
therapy	I-I
on	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
post	I-P
-	I-P
traumatic	I-P
stress	I-P
symptoms	I-P
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
111	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
near	I-P
the	I-P
discharge	I-P
stage	I-P
with	I-P
positive	I-P
screening	I-P
results	I-P
for	I-P
posttraumatic	I-P
stress	I-P
symptoms	I-P
(	I-P
PTSS	I-P
)	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
either	O
the	O
study	O
group	O
or	O
the	O
control	O
group	O
.	O

The	O
study	O
group	O
received	O
NET	B-I
and	O
personalized	B-I
psychological	I-I
intervention	I-I
,	O
while	O
the	O
control	O
group	O
only	O
received	O
personalized	B-C
psychological	I-C
intervention	I-C
.	O

PTSS	B-O
,	O
depression	B-O
,	O
anxiety	B-O
and	O
sleep	B-O
quality	I-O
were	O
measured	O
pre	O
-	O
and	O
post	O
-	O
intervention	O
to	O
evaluate	O
the	O
effect	O
of	O
NET	B-I
.	O

This	O
trial	O
was	O
registered	O
with	O
the	O
International	O
Standard	O
Randomized	O
Clinical	O
Trial	O
Registry	O
(	O
No	O
.	O

ChiCTR2000039369	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
CORonavirus	O
-	O
19	O
mild	O
to	O
moderate	O
pneumonia	O
Management	O
with	O
blood	B-I
Ozonization	I-I
in	O
patients	B-P
with	I-P
Respiratory	I-P
failure	I-P
(	O
CORMOR	O
)	O
multicentric	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
trial	O
(	O
ClinicalTrial	O
.	O
gov	O
NCT04388514	O
)	O
was	O
conducted	O
in	O
four	O
different	O
Italian	O
centers	O
(	O
April	O
-	O
October	O
2020	O
)	O
.	O

Patients	O
were	O
treated	O
according	O
to	O
best	B-I
available	I-I
standard	I-I
of	I-I
care	I-I
(	I-I
SoC	I-I
)	I-I
therapy	I-I
,	O
with	B-I
or	O
without	B-C
O3	I-C
-	I-C
autohemotherapy	I-C
(	I-C
O3	I-C
-	I-C
AHT	I-C
)	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
2	I-I
-	I-I
Week	I-I
5000	I-I
IU	I-I
versus	O
1000	B-C
IU	I-C
Vitamin	I-C
D3	I-C
Supplementation	I-C
on	O
Recovery	O
of	O
Symptoms	O
in	O
Patients	B-P
with	I-P
Mild	I-P
to	I-P
Moderate	I-P
Covid	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
69	I-P
reverse	I-P
transcriptase	I-P
polymerase	I-P
chain	I-P
reaction	I-P
(	I-P
RT	I-P
-	I-P
PCR	I-P
)	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
positive	I-P
adults	I-P
who	I-P
were	I-P
hospitalized	I-P
for	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
disease	I-P
were	O
allocated	O
to	O
receive	O
once	B-I
daily	I-I
for	I-I
2	I-I
weeks	I-I
either	I-I
5000	I-I
IU	I-I
oral	I-I
vitamin	I-I
D3	I-I
(	O
n	O
=	O
36	O
,	O
21	O
males	O
;	O
15	O
females	O
)	O
or	O
1000	B-C
IU	I-C
oral	I-C
vitamin	I-C
D3	I-C
(	O
standard	O
control	O
)	O
(	O
n	O
=	O
33	O
,	O
13	O
males	O
;	O
20	O
females	O
)	O
.	O

Anthropometrics	B-O
were	O
measured	O
and	O
blood	O
samples	O
were	O
taken	O
pre	O
-	O
and	O
post	O
-	O
supplementation	O
.	O

Fasting	B-O
blood	I-O
glucose	I-O
,	O
lipids	B-O
,	O
serum	B-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
,	O
and	O
inflammatory	B-O
markers	I-O
were	O
measured	O
.	O

COVID	B-O
-	I-O
19	I-O
symptoms	I-O
were	O
noted	O
on	O
admission	O
and	O
monitored	O
until	O
full	O
recovery	O
.	O

-DOCSTART-	O

Title	O
:	O
Ivermectin	B-I
to	O
prevent	O
hospitalizations	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
IVERCOR	O
-	O
COVID19	O
)	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
was	O
conducted	O
in	O
non	B-P
-	I-P
hospitalized	I-P
individuals	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
in	I-P
Corrientes	I-P
,	I-P
Argentina	I-P
.	O

Patients	B-P
with	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
positive	I-P
nasal	I-P
swabs	I-P
were	O
contacted	O
within	O
48	O
h	O
by	O
telephone	O
to	O
invite	O
them	O
to	O
participate	O
.	O

The	O
trial	O
randomized	O
501	B-P
patients	I-P
between	I-P
August	I-P
19	I-P
th	I-P
2020	I-P
and	I-P
February	I-P
22	I-P
nd	I-P
2021	I-P
.	O

Patients	O
were	O
randomized	O
to	O
ivermectin	B-I
(	O
N	O
=	O
250	O
)	O
or	O
placebo	B-C
(	O
N	O
=	O
251	O
)	O
arms	O
in	O
a	O
staggered	O
dose	O
,	O
according	O
to	O
the	O
patient	O
'	O
s	O
weight	O
,	O
for	O
2	O
days	O
.	O

The	O
efficacy	O
of	O
ivermectin	B-I
to	O
prevent	O
hospitalizations	B-O
was	O
evaluated	O
as	O
primary	O
outcome	O
.	O

We	O
evaluated	O
secondary	O
outcomes	O
in	O
relationship	O
to	O
safety	B-O
and	O
other	O
efficacy	O
end	O
points	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomised	O
,	O
controlled	O
,	O
open	O
label	O
,	O
multicentre	O
clinical	O
trial	O
to	O
explore	O
safety	O
and	O
efficacy	O
of	O
hyperbaric	B-I
oxygen	I-I
for	O
preventing	O
ICU	O
admission	O
,	O
morbidity	O
and	O
mortality	O
in	O
adult	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
,	O
controlled	O
,	O
phase	O
II	O
,	O
open	O
label	O
,	O
multicentre	O
trial	O
.	O

200	B-P
subjects	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
at	I-P
least	I-P
two	I-P
risk	I-P
factors	I-P
for	I-P
mortality	I-P
will	O
be	O
included	O
.	O

Baseline	O
clinical	O
data	O
and	O
blood	O
samples	O
will	O
be	O
collected	O
before	O
randomisation	O
and	O
repeated	O
daily	O
for	O
7	O
days	O
,	O
at	O
days	O
14	O
and	O
30	O
.	O

Subjects	O
will	O
be	O
randomised	O
with	O
a	O
computer	O
-	O
based	O
system	O
to	O
HBO	B-I
,	O
maximum	O
five	O
times	O
during	O
the	O
first	O
7	O
days	O
plus	O
best	B-I
practice	I-I
treatment	I-I
or	O
only	B-C
best	I-C
practice	I-C
treatment	I-C
.	O

The	O
primary	O
endpoint	O
,	O
ICU	B-O
admission	I-O
,	O
is	O
defined	O
by	O
criteria	B-O
for	I-O
selection	I-O
for	I-O
ICU	I-O
.	O

We	O
will	O
evaluate	O
if	O
HBO	B-I
mitigates	O
the	B-O
inflammatory	I-O
reaction	I-O
in	I-O
COVID	I-O
-	I-O
19	I-O
using	O
molecular	O
analyses	O
.	O

All	O
parameters	O
are	O
recorded	O
in	O
an	O
electronic	O
case	O
report	O
form	O
.	O

An	O
independent	O
Data	O
Safety	O
Monitoring	O
Board	O
will	O
review	O
the	B-O
safety	I-O
parameters	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Umbilical	B-I
Cord	I-I
-	I-I
derived	I-I
Mesenchymal	I-I
Stem	I-I
Cells	I-I
modulate	O
TNF	O
and	O
soluble	O
TNF	O
Receptor	O
2	O
(	O
sTNFR2	O
)	O
in	O
COVID	B-P
-	I-P
19	I-P
ARDS	I-P
patients	I-P
.	O

METHODS	O
:	O
We	O
analyzed	O
plasma	O
samples	O
from	O
subjects	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
ARDS	I-P
(	I-P
n=24	I-P
)	I-P
enrolled	O
in	O
a	O
Phase	O
1	O
/	O
2	O
a	O
randomized	O
controlled	O
trial	O
of	O
UC	B-I
-	I-I
MSC	I-I
treatment	I-I
.	O

Plasma	O
samples	O
were	O
obtained	O
at	O
Day	O
0	O
(	O
baseline	O
,	O
before	O
UC	O
-	O
MSC	O
or	O
control	O
infusion	O
)	O
,	O
and	O
Day	O
6	O
post	O
infusion	O
.	O

Plasma	B-O
concentrations	I-O
of	I-O
sTNFR2	I-O
,	O
TNF?	B-O
,	O
and	O
TNF?	B-O
were	O
evaluated	O
using	O
a	B-O
quantitative	I-O
multiplex	I-O
protein	I-O
array	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Standard	B-C
prophylactic	I-C
versus	O
intermediate	B-I
dose	I-I
enoxaparin	I-I
in	O
adults	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
multi	O
-	O
center	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multi	O
-	O
center	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
comparing	O
standard	B-C
prophylactic	I-C
dose	I-C
versus	O
intermediate	B-I
dose	I-I
enoxaparin	I-I
in	O
adults	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
admitted	I-P
to	I-P
an	I-P
intensive	I-P
care	I-P
unit	I-P
(	I-P
ICU	I-P
)	I-P
and	I-P
/	I-P
or	I-P
had	I-P
laboratory	I-P
evidence	I-P
of	I-P
coagulopathy	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
standard	B-C
prophylactic	I-C
dose	I-C
enoxaparin	I-C
or	O
intermediate	B-I
weight	I-I
-	I-I
adjusted	I-I
dose	I-I
enoxaparin	I-I
.	O

The	O
primary	O
outcome	O
was	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
at	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
arterial	B-O
or	O
venous	B-O
thromboembolism	I-O
and	O
major	B-O
bleeding	I-O
.	O

